Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Lower mitochondrial DNA and altered mitochondrial fuel metabolism in HIV-exposed uninfected infants in Cameroon.

Jao J, Powis KM, Kirmse B, Yu C, Epie F, Nshom E, Abrams EJ, Sperling RS, Leroith D, Geffner ME, Kurland IJ, Côté HCF.

AIDS. 2017 Nov 28;31(18):2475-2481. doi: 10.1097/QAD.0000000000001647.

PMID:
28926411
2.

Birth Weight and Preterm Delivery Outcomes of Perinatally vs Nonperinatally Human Immunodeficiency Virus-Infected Pregnant Women in the United States: Results From the PHACS SMARTT Study and IMPAACT P1025 Protocol.

Jao J, Kacanek D, Williams PL, Geffner ME, Livingston EG, Sperling RS, Patel K, Bardeguez AD, Burchett SK, Chakhtoura N, Scott GB, Van Dyke RB, Abrams EJ; Pediatric HIV/AIDS Cohort Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials P1025 Protocol; Pediatric HIV/AIDS Cohort Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials P1025 Protocol.

Clin Infect Dis. 2017 Sep 15;65(6):982-989. doi: 10.1093/cid/cix488.

PMID:
28575201
3.

Severe Vitamin D Deficiency in Human Immunodeficiency Virus-Infected Pregnant Women is Associated with Preterm Birth.

Jao J, Freimanis L, Mussi-Pinhata MM, Cohen RA, Monteiro JP, Cruz ML, Branch A, Sperling RS, Siberry GK; NISDI LILAC Protocol.

Am J Perinatol. 2017 Apr;34(5):486-492. doi: 10.1055/s-0036-1593536. Epub 2016 Oct 7.

4.

Revolutionizing Alzheimer's disease and clinical trials through biomarkers.

Mattsson N, Carrillo MC, Dean RA, Devous MD Sr, Nikolcheva T, Pesini P, Salter H, Potter WZ, Sperling RS, Bateman RJ, Bain LJ, Liu E.

Alzheimers Dement (Amst). 2015 Oct 3;1(4):412-9. doi: 10.1016/j.dadm.2015.09.001. eCollection 2015 Dec. Review.

5.

Lower Preprandial Insulin and Altered Fuel Use in HIV/Antiretroviral-Exposed Infants in Cameroon.

Jao J, Kirmse B, Yu C, Qiu Y, Powis K, Nshom E, Epie F, Tih PM, Sperling RS, Abrams EJ, Geffner ME, LeRoith D, Kurland IJ.

J Clin Endocrinol Metab. 2015 Sep;100(9):3260-9. doi: 10.1210/JC.2015-2198. Epub 2015 Jul 2.

6.

Low vitamin D status among pregnant Latin American and Caribbean women with HIV Infection.

Jao J, Freimanis L, Mussi-Pinhata MM, Cohen RA, Monteiro JP, Cruz ML, Sperling RS, Branch A, Siberry GK; NISDI LILAC Protocol.

Int J Gynaecol Obstet. 2015 Jul;130(1):54-8. doi: 10.1016/j.ijgo.2015.01.017. Epub 2015 Apr 11.

7.

Salvage Regimens Containing Darunavir, Etravirine, Raltegravir, or Enfuvirtide in Highly Treatment-Experienced Perinatally Infected Pregnant Women.

Shust GF, Jao J, Rodriguez-Caprio G, Posada R, Chen KT, Averitt A, Sperling RS.

J Pediatric Infect Dis Soc. 2014 Sep;3(3):246-50. doi: 10.1093/jpids/pit019. Epub 2013 Apr 12.

8.

Growth patterns in the first year of life differ in infants born to perinatally vs. nonperinatally HIV-infected women.

Jao J, Agwu A, Mhango G, Kim A, Park K, Posada R, Abrams EJ, Hutton N, Sperling RS.

AIDS. 2015 Jan 2;29(1):111-6. doi: 10.1097/QAD.0000000000000501.

9.

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.

Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, David MP, Lin L, Struyf F, Dubin G; HPV-010 Study Group.

Hum Vaccin Immunother. 2014;10(12):3435-45. doi: 10.4161/hv.36121.

10.

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.

Einstein MH, Levin MJ, Chatterjee A, Chakhtoura N, Takacs P, Catteau G, Dessy FJ, Moris P, Lin L, Struyf F, Dubin G; HPV-010 Study Group.

Hum Vaccin Immunother. 2014;10(12):3455-65. doi: 10.4161/hv.36117.

11.

Gestational diabetes mellitus in HIV-infected and -uninfected pregnant women in Cameroon.

Jao J, Wong M, Van Dyke RB, Geffner M, Nshom E, Palmer D, Muffih PT, Abrams EJ, Sperling RS, Leroith D.

Diabetes Care. 2013 Sep;36(9):e141-2. doi: 10.2337/dc13-0968. No abstract available.

12.

Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia.

Atrio JM, Sperling RS, Posada R, Rodriguez Caprio G, Chen KT.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e158-9. doi: 10.1097/QAI.0b013e31829baf03. No abstract available.

PMID:
23970241
13.

The influence of pregnancy on systemic immunity.

Pazos M, Sperling RS, Moran TM, Kraus TA.

Immunol Res. 2012 Dec;54(1-3):254-61. doi: 10.1007/s12026-012-8303-9. Review.

PMID:
22447351
14.

Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum.

Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J, Singh T, Kellerman L, Moran TM.

Obstet Gynecol. 2012 Mar;119(3):631-9. doi: 10.1097/AOG.0b013e318244ed20.

15.

Small for gestational age birth outcomes in pregnant women with perinatally acquired HIV.

Jao J, Sigel KM, Chen KT, Rodriguez-Caprio G, Posada R, Shust G, Wisnivesky J, Abrams EJ, Sperling RS.

AIDS. 2012 Apr 24;26(7):855-9. doi: 10.1097/QAD.0b013e328351f6ef.

16.

Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study.

Kraus TA, Engel SM, Sperling RS, Kellerman L, Lo Y, Wallenstein S, Escribese MM, Garrido JL, Singh T, Loubeau M, Moran TM.

J Clin Immunol. 2012 Apr;32(2):300-11. doi: 10.1007/s10875-011-9627-2. Epub 2011 Dec 24.

PMID:
22198680
17.

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Meric D, Dessy FJ, Datta SK, Descamps D, Dubin G; HPV-010 Study Group.

Hum Vaccin. 2011 Dec;7(12):1343-58. doi: 10.4161/hv.7.12.18281. Epub 2011 Dec 1.

18.

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, Moris P, Giannini SL, Schuind A, Datta SK, Descamps D; HPV-010 Study Group.

Hum Vaccin. 2011 Dec;7(12):1359-73. doi: 10.4161/hv.7.12.18282. Epub 2011 Dec 1.

19.

Peripheral blood cytokine profiling during pregnancy and post-partum periods.

Kraus TA, Sperling RS, Engel SM, Lo Y, Kellerman L, Singh T, Loubeau M, Ge Y, Garrido JL, Rodríguez-García M, Moran TM.

Am J Reprod Immunol. 2010 Dec;64(6):411-26. doi: 10.1111/j.1600-0897.2010.00889.x. Epub 2010 Aug 16.

PMID:
20712812
20.

Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.

Brogly SB, Abzug MJ, Watts DH, Cunningham CK, Williams PL, Oleske J, Conway D, Sperling RS, Spiegel H, Van Dyke RB.

Pediatr Infect Dis J. 2010 Aug;29(8):721-7. doi: 10.1097/INF.0b013e3181e74a2f.

Supplemental Content

Loading ...
Support Center